2022 World Conference on Lung Cancer (ePosters)-EP05.01-018. Chemoradiotherapy Followed by Durvalumab in Unresectable Locally Advanced NSCLC- A Single Institution Experience in Croatia

EP05.01-018. Chemoradiotherapy Followed by Durvalumab in Unresectable Locally Advanced NSCLC- A Single Institution Experience in Croatia

Back to course

Pdf Summary

A study conducted at the University Hospital Centre Zagreb in Croatia analyzed the real-world outcomes of patients with unresectable locally advanced non-small cell lung cancer (NSCLC) who were treated with chemoradiotherapy followed by consolidation durvalumab. The PACIFIC trial established that durvalumab consolidation improved progression-free survival and overall survival in this patient population. The study included 42 patients, with a mean age of 62.6 years, of which 78.6% were male. Squamous histology was observed in 52.3% of patients, while 47.6% had non-squamous NSCLC. PD-L1 expression was 50% in 45.2% of patients. Concurrent chemoradiotherapy was administered to 83.3% of patients, while 16.7% received sequential chemoradiotherapy. Durvalumab treatment was initiated within 45 days of radiation therapy completion. Adverse events, such as pneumonitis and thyroid function disorders, were mostly mild to moderate. The median progression-free survival for the entire cohort was 24.1 months. Female patients had a significantly longer progression-free survival. PFS benefit was also observed in patients with PD-L1 expression ≥50% and those who underwent concurrent chemoradiotherapy. The median overall survival was not reached, with a cumulative survival proportion of 66.7% after a median of 32 months of treatment. The study concludes that the findings support the survival benefit and safety of durvalumab consolidation in patients with locally advanced NSCLC. However, further research is required to identify additional factors that contribute to the efficacy of durvalumab in this subset of NSCLC patients.

Asset Subtitle

Marko Jakopovic

Meta Tag

Speaker Marko Jakopovic

Topic Locally Advanced Non-small Cell Lung Cancer - Chemoradiotherapy and Radiotherapy

Keywords

University Hospital Centre Zagreb

Croatia

real-world outcomes

unresectable locally advanced non-small cell lung cancer

NSCLC

chemoradiotherapy

consolidation durvalumab

PACIFIC trial

progression-free survival

overall survival